
Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology.
Following a substantial strategic equity investment from AstraZeneca (NASDAQ: AZN) and a strengthened financial position reported in its full-year 2024 results, Cellectis has entered a potentially pivotal stage in its market narrative.